Drugs / LUCORIDALINES

Trials 9

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT01669772 Mar 2012 → Feb 2013 — Myung-gui Choi Completed No outcome recorded
Phase 21 trial
Phase 2 NCT02365701 Jun 2015 → Feb 2018 dyspepsia Dong-A ST Co., Ltd. Completed No outcome recorded
Phase 45 trials · 2 met primary
Phase 4 NCT07686679 Jul 2026 → Oct 2027 expected dyspepsia Dong-A ST Co., Ltd. Not yet recruiting No outcome recorded
Phase 4 NCT02775591 Apr 2016 → Jun 2018 Parkinson disease, dyspepsia Seoul National University Hospital Completed Met primary
Phase 4 NCT03022201 May 2013 → May 2016 Parkinson disease Seoul National University Hospital Completed Met primary
Phase 4 NCT01817465 Aug 2012 → Mar 2014 dyspepsia Dong-A ST Co., Ltd. Completed No outcome recorded
Phase 4 NCT01719575 Mar → Nov 2012 — Dong-A Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase not applicable2 trials
— NCT07096921 Jul 2025 → Mar 2026 overdue dyspepsia Eunpyeong St. Mary's Hospital Active not recruiting No outcome recorded
— NCT02162316 Jul 2014 → Jun 2015 dyspepsia Chung-Ang University Hospital Unknown No outcome recorded
Comparator or background therapy4 trials
Phase 3 NCT02533349 Comparator May → Dec 2016 gastroesophageal reflux disease Samsung Medical Center Unknown No outcome recorded
— NCT04350346 Comparator Mar 2020 → Sep 2021 gallstones Yonsei University Unknown No outcome recorded
— NCT02151708 Comparator Jun 2014 → Feb 2015 dyspepsia Samsung Medical Center Unknown No outcome recorded
— NCT02091635 Comparator Aug → Oct 2013 dyspepsia Samsung Medical Center Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2014-10-22 Dong-A ST Co., Ltd. Regulatory 동아ST, 천연물신약 기능성소화불량증 치료제 ‘모티리톤’ 미국 FDA 임상 2상 시험 승인 donga-st.com ↗
동아에스티(대표이사 사장 박찬일)는 미국 FDA가 천연물신약 기능성소화불량증 치료제 ‘모티리톤(Motilitone)’의 미국 임상 2상 시험을 승인했다고 22일 밝혔다.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as LUCORIDALINES ChEMBL registry synonym — accepted as the source's own label CHEMBL5314637 ↗
Known as DA-9701 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07096921 ↗
4

NCT03022201 ↗

NCT07686679 ↗

NCT02775591 ↗

NCT01669772 ↗

Known as motilitone “Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.” NCT01669772 ↗
8

NCT02365701 ↗

NCT02162316 ↗

NCT01817465 ↗

NCT02533349 ↗

NCT02091635 ↗

NCT02151708 ↗

NCT04350346 ↗

NCT01719575 ↗

Action Activate “It stimulates 5-HT4 receptor as a gastrointestinal motility accelerator to increase acetylcholine secretion and contract smooth muscle.” NCT04350346 ↗
Modality Traditional medicine (herbal / TCM) “DA-9701 (Motilitone) is recently developed herbal medication” NCT02775591 ↗
Route Oral “in tablet form, to be taken 3 times daily” NCT02365701 ↗